FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atrial Flutter
CryoCor Provides PMA Update
March 15th, 2007
CryoCor, Inc. (NASDAQ:CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced that, based upon additional information from CryoCor, the U.S. Food and Drug Administration, or FDA, may no longer need to convene an Advisory Panel meeting to render a decision on CryoCor's PMA for the treatment of atrial flutter. The additional information CryoCor is providing indicates a higher chronic effectiveness than in the amended PMA filing. The FDA has cancelled CryoCor's previously announced panel meeting while they take time to review this new information. CryoCor now expects a final decision on its PMA for the treatment of atrial flutter by August 2007, instead of...
Source: FDA Law Weekly (2007-03-15)
|
